Loading...
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, a...
Na minha lista:
Udgivet i: | Blood |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
American Society of Hematology
2015
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4424415/ https://ncbi.nlm.nih.gov/pubmed/25755291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-585869 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|